| Oncology | Prior Authorization in Medical Oncology | Planning | - se Case Plan finalized by clinical and technical stakeholders
- Governance approval is underway and is the key remaining step to move to Execution
| - Presented to OpCo on May 27
- Published Oncologist Listening Sessions article
- Finalized Use Case Plan
- Established 5-member Clinical Advisory Board
- Reached out to HL7 WGs to share project and determine sponsorship
| - Present to SteerCo on June 10
- Seek approval to move to Execution
- Attend Clinical Decision Support and Financial Planning HL7 WGs meetings
- Post MOPA Project Proposal due on June 1
| To be defined | | None | Q2 2026 | |
| Cardiovascular Health | Hypertension Management | Execution | - Execution is progressing with implementation planning underway
- Omron has committed to support CardX SMBP IG work with El Rio
- Technical team identified for IG, Omron, and Epic integration planning
| - Secured Omron leadership support
- Identified El Rio Public Health Department as implementation partner
- Identified technical team for integration planning.
| - Kick off Omron, El Rio, and CardX technical integration planning
- Continue HTN IG Reference Guide development
- Re-introduce Omron to CodeX for membership
- Resume HTN Management leadership meetings.
| | | CIC | Q2 2026 | |
| Cardiac Implantable Electronic Device - Alert Management | Execution | - Execution is progressing
- Clinical scenarios and IG build are advancing
- Pilot site discussions are underway
| - Advanced manufacturer alert planning
- BMP team began developing clinical scenarios
- Continued IG build using IDCO terminology.
- Presented CIED progress at the World Forum meeting at HRS
| - Finalize clinical scenarios for alert phase
- Continue pilot site discussions and planning
| Dr. John Windle & James Tcheng | | CIC | 2027 | |
| mCARD | Discovery | - Discovery is well advanced
- Initial terminology mapping, business proposal, and planning activities are underway
- Retreat outputs have been converted into action items and work assignments
| - Mapped first 5 terms
- Drafted mCARD business proposal
- Completed mCARD retreat at UNMC
- Defined action items for metadata, technical mapping, gap analysis, project planning, and HL7 proposal development
| - Schedule bi-weekly mCARD technical meetings
- Schedule mCARD leadership meetings
- Send final business case to potential community members
| | | CIC | Q2 2026 | |
| Genomics | Data Exchange | Execution | - Pilot 1 is complete and provided a strong foundation
- The use case is shifting from technical validation to real-world application
- Leadership alignment is needed before advancing the next pilot
| - Completed Pilot 1 with successful biomarker data ingestion
- Validated lab-to-EHR data flow
- Identified real-world implementation gaps
- Aligned on separating standards/ modeling work from focused pilot work
- Reintroduced the Champion role and clarified expectations.
| - Define next pilot focus and success criteria
- Refresh Confluence page and centralize files
- Continue biomarker list refinement
- Explore updated naming, positioning, and messaging
- Hold technical work until scope is confirmed
| | | Clinical Genomics | Q4 2026 | |
| Pathogen Genomics | Execution | - Execution has started, but leadership restructuring is underway
- Editorial Board work is progressing
- DAM development requires a pathogen genomics SME
| - Continued bi-weekly Editorial Board meetings
- Assigned writing/resource roles by section
- Confirmed Arthur as Editorial Group lead
- Advanced stakeholder needs assessment planning, with SFU leading ethics approval
- Approved revised UCC co-lead structure
| - Recruit pathogen genomics SME co-lead
- Confirm project coordinator role and operating model
- Resume stakeholder survey development after leadership structure is finalized
- Identify SME to lead pathogen genomics DAM content and decisions
| None | Interim UCCs: Bret Heale / WilliamHsiao / Emma Griffith | Clinical Genomics | 2027 | |
| Molecular Tumor Board | Execution | - Execution has started following completion of Planning
- Key technical workstreams have been defined
- Leadership structure needs to be confirmed to support execution
| - Completed Planning Phase activities
- Refined key technical subtasks, including data element dictionary and variant annotation representation
- Advanced use case into Execution
| - Confirm Execution Phase workplan
- Confirm leadership and coordination roles
- Begin advancing defined technical workstreams
| None | | Clinical Genomics | 2027 | |
| Pharmacovigilance and Risk Avoidance | Execution | - Execution is advancing from planning into pilot work
- Pilot roles, participation model, and stakeholder expectations are being clarified
- Specialty pharmacy input is critical to pilot design and scaling
| - Held strategy calls on specialty pharmacy workflows and pilot learnings
- Confirmed involvement across key pilot roles, including health systems, REMS administrators, specialty pharmacies, intermediaries, and standards partners.
- Defined separate tracks for pilot participants and long-term strategy advisors
- Confirmed approach to start with a small synthetic pilot before moving to real-world pilot testing
| - Finalize pilot participant list and commitments
- Schedule formal pilot kickoff and meeting cadence
- Share role-based guidance for pilot participants
- Continue outreach to specialty pharmacies, distribution, and PBM stakeholders
- Select initial pilot medication(s).
| None | | Clinical Genomics | Q4 2026 | |
